Ruxolitinib Cream Safe for Kids with Eczema

Managing atopic dermatitis (eczema) in children requires treatments that balance long-term effectiveness with safety, avoiding the potential drawbacks of continuous corticosteroid use. A phase 3 study published in the Journal of the American Academy of Dermatology evaluated the long-term safety and efficacy of as-needed ruxolitinib cream in children aged 2–11 years.

The study followed 282 children with mild-to-moderate eczema over a 44-week long-term safety period, applying the cream strictly to active lesions as needed.

Key Findings from the Study

Bullet Well Tolerated: As-needed application of ruxolitinib cream was well tolerated over 44 weeks, with no new safety signals, deaths, or major cardiovascular events reported.

Bullet Sustained Disease Control: At week 52, roughly 72% to 79% of children maintained clear or almost clear skin, with minimal affected body surface area.

Bullet Significant Time Off Treatment: Children initially treated with ruxolitinib spent a median of 50.5% of the study period completely off treatment after their lesions cleared, restarting only when necessary.

Bullet Symptom Relief: Both itch and sleep scores showed noticeable improvements with the therapy.

Clinical Implications

For young patients suffering from atopic dermatitis, as-needed ruxolitinib cream offers a promising, corticosteroid-free alternative that maintains long-term disease control while minimizing unnecessary daily medication exposure.

Source: Medscape